Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Could Johnson & Johnson’s talcum powder litigation, now in its second decade, come to an end in 2025? Or are more legal and legislative battles on the horizon? Johnson & Johnson enters the New ...

Drugmaker Johnson & Johnson must pay $572m (£468m ... The State failed to present evidence that the company's products or actions caused a public nuisance in Oklahoma," it said.

Johnson & Johnson has won Food and Drug Administration ... patients with generalized myasthenia gravis. The New Brunswick, N.J., pharmaceutical giant on Thursday said nipocalimab, if approved ...

Johnson & Johnson says the safety of its talcum ... in damages to 22 women who alleged that its talc products caused them to develop ovarian cancer. A jury in the US state of Missouri initially ...